News Opinion CV Team Dispatch September 2025 Dispatch for the CV Team L.A. McKeown September 30, 2025
News Daily News CVD Still the Leading Cause of Death and Disease Globally Michael O'Riordan September 24, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ESC 2025 High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors Caitlin E. Cox August 29, 2025
News Daily News Evolocumab Gains Expanded Indication for Primary Prevention Michael O'Riordan August 26, 2025
News Daily News Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol Michael O'Riordan August 06, 2025
News Conference News SCCT 2025 Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR Yael L. Maxwell July 28, 2025
News Daily News CCTA Bests CV Risk Scores for Bolstering Lifestyle Changes, Medication Uptake Yael L. Maxwell June 25, 2025
News Conference News EAS 2025 Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM Yael L. Maxwell May 08, 2025
News Daily News Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention Michael O'Riordan May 07, 2025
News Daily News Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE Caitlin E. Cox April 23, 2025
News Daily News Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy Caitlin E. Cox April 14, 2025
News Daily News Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD Michael O'Riordan March 06, 2025
News Daily News Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care Michael O'Riordan February 27, 2025
News Daily News Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE Yael L. Maxwell February 14, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain Yael L. Maxwell January 13, 2025